These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9889441)

  • 21. Contingent methadone delivery: effects on illicit-opiate use.
    Higgins ST; Stitzer ML; Bigelow GE; Liebson IA
    Drug Alcohol Depend; 1986 Jul; 17(4):311-22. PubMed ID: 3757767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methadone dosage and retention: an examination of the 60 mg/day threshold.
    Brady TM; Salvucci S; Sverdlov LS; Male A; Kyeyune H; Sikali E; DeSale S; Yu P
    J Addict Dis; 2005; 24(3):23-47. PubMed ID: 16186081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term follow-up of clients of high- and low-dose methadone programs.
    McGlothlin WH; Anglin MD
    Arch Gen Psychiatry; 1981 Sep; 38(9):1055-63. PubMed ID: 7283663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of accessing antiretroviral therapy among HIV-positive drug users in China's National Methadone Maintenance Treatment Programme.
    Zhao Y; Shi CX; McGoogan JM; Rou K; Zhang F; Wu Z
    Addiction; 2015 Jan; 110 Suppl 1(Suppl 1):40-50. PubMed ID: 25533863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users.
    Strain EC; Stitzer ML; Liebson IA; Bigelow GE
    Psychopharmacology (Berl); 1994 Dec; 116(4):401-6. PubMed ID: 7701040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An alternative program for methadone maintenance dropouts: description and preliminary data.
    Goldstein MF; Deren S; Beardsley M; Richman BL
    Mt Sinai J Med; 2001 Jan; 68(1):33-40. PubMed ID: 11135504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. J-shaped relationship between supervised methadone consumption and retention in methadone maintenance treatment (MMT) in primary care: National cohort study.
    Cousins G; Boland F; Barry J; Lyons S; Keenan E; O'Driscoll D; Bennett K; Fahey T
    Drug Alcohol Depend; 2017 Apr; 173():126-131. PubMed ID: 28232249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Limit setting on drug abuse in methadone maintenance patients.
    McCarthy JJ; Borders OT
    Am J Psychiatry; 1985 Dec; 142(12):1419-23. PubMed ID: 4073304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retention rates among New York City methadone patients: a response to Bayer and Koenigsberg.
    Des Jarlais DC
    Int J Addict; 1982 Jul; 17(5):929-30. PubMed ID: 7129708
    [No Abstract]   [Full Text] [Related]  

  • 30. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia.
    Winstock AR; Lea T; Sheridan J
    Int J Drug Policy; 2008 Dec; 19(6):450-8. PubMed ID: 18359216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physicians' attitudes and retention of patients in their methadone maintenance programs.
    Caplehorn JR; Irwig L; Saunders JB
    Subst Use Misuse; 1996 May; 31(6):663-77. PubMed ID: 8816115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Three-year retention in methadone opioid agonist treatment: A survival analysis of clients by dose, area deprivation, and availability of alcohol and cannabis outlets.
    Amiri S; Hirchak K; Lutz R; McDonell MG; McPherson SM; Roll JM; Amram O
    Drug Alcohol Depend; 2018 Dec; 193():63-68. PubMed ID: 30340146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The perceptions of program directors and clients regarding the efficacy of methadone treatment.
    Mavis BE; DeVoss GH; Stöffelmayr BE
    Int J Addict; 1991 Jul; 26(7):769-76. PubMed ID: 1660042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A 5-year evaluation of a methadone medical maintenance program.
    Harris KA; Arnsten JH; Joseph H; Hecht J; Marion I; Juliana P; Gourevitch MN
    J Subst Abuse Treat; 2006 Dec; 31(4):433-8. PubMed ID: 17084798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retention in methadone maintenance and heroin addicts' risk of death.
    Caplehorn JR; Dalton MS; Cluff MC; Petrenas AM
    Addiction; 1994 Feb; 89(2):203-9. PubMed ID: 8173486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Re-entry and related predictors among HIV-infected clients receiving methadone maintenance treatment in Guangdong province, China.
    Luo X; Gong X; Zhao P; Zou X; Chen W; Ling L
    Biosci Trends; 2017 Jul; 11(3):282-291. PubMed ID: 28420822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved treatment-retention for patients receiving methadone dosing within the clinic providing physician and other health services (onsite) versus dosing at community (offsite) pharmacies.
    Gauthier G; Eibl JK; Marsh DC
    Drug Alcohol Depend; 2018 Oct; 191():1-5. PubMed ID: 30064001
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methadone maintenance treatment: outcomes from the Otago methadone programme.
    Dore GM; Walker JD; Paice JR; Clarkson S
    N Z Med J; 1999 Nov; 112(1100):442-5. PubMed ID: 10678242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
    Mattick RP; Kimber J; Breen C; Davoli M
    Cochrane Database Syst Rev; 2002; (4):CD002207. PubMed ID: 12519569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Club-based drug use and its associated risk factors among HIV-positive methadone maintenance treatment clients].
    Jiang H; Cao X; Wang C; Luo W; Rou K; Li J; Zhang B; Wu Z
    Zhonghua Liu Xing Bing Xue Za Zhi; 2014 Aug; 35(8):905-8. PubMed ID: 25376680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.